CClinicalTrials.gg
RecruitingNCT07569666Updated May 6, 2026

Exososmes in Atrophic Scars Management

An interventional study of Intralesional exosomes and Intralesional Saline in Atrophic Scar, sponsored by Zagazig University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).
  • Started Jun 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Lay Summary (Simple Explanation)

Atrophic scars are depressed scars that form when the skin does not heal properly, commonly seen after acne or injuries. These scars can affect appearance and confidence, and current treatments may not always give satisfactory results.

This study aims to evaluate a new treatment using exosomes, which are tiny particles naturally released by cells that help in skin repair and regeneration. Researchers will compare the effect of injecting exosomes directly into scars versus injecting a simple saltwater solution (saline), which serves as a control.

Participants will be randomly assigned to receive either exosome injections or saline injections. Neither the patient nor the evaluator may know which treatment is given, to ensure fair comparison.

The goal is to determine whether exosomes can safely and effectively improve the appearance and texture of atrophic scars.

02

Conditions studied

  • Atrophic Scar
03

In context

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Age >18 years

  • Either gender
  • Scars of any duration
  • Multiple scars at one side or both sides of the face.
  • Patients are willing to sign written informed consent statements before beginning treatment.

Exclusion criteria

Exclusion Criteria:

  • Pregnant females.
  • Patients with one scar.
  • Hypersensitivity to any of the used treatments.
  • Patient with infection at the site of the scar.
  • Patients with unrealistic expectations.
  • Patient refusing to sign on the consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Exosomes

    Other: Intralesional exosomes

  • Placebo comparator
    Saline

    Other: Intralesional Saline

Interventions

  • OtherIntralesional exosomes

    exosomes are injected within the substance of the scar.

  • OtherIntralesional Saline

    all patients will receive both, exosomes and saline, each injected into one scar.

06

What researchers measure

Primary outcomes

  1. modified Manchester Scar Scale

    Scar appearance was assessed using the Modified Manchester Scar Scale. The Modified Manchester Scar Scale ranges from 4 to 24, with lower scores indicating better scar appearance and higher scores indicating worse scar appearance

    Time frame: 3 months after 4 biweekly sessions

Secondary outcomes

  1. Scar thickness measurement in millimetres by Ultrasound examination

    Scar characteristics, including scar thickness and echogenicity, will be assessed using high-frequency ultrasound examination. Scar thickness will be measured in millimeters, and changes from baseline to follow-up will be summarized. Higher scar thickness values indicate greater scar tissue thickness

    Time frame: 3 months after 4 biweekly sessions

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569666
Lead sponsor
Zagazig University
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 15, 2025
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 6, 2026

Study contacts

mona Elradi
Contact
monaelradi@medicine.zu.edu.eg
+201067070550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion